Literature DB >> 35397087

miR-211-3p enhances induction chemotherapy insensitivity by upregulating CSF2/CCL20/TNF signaling in hypopharyngeal squamous cell carcinoma.

Lingwa Wang1, Ru Wang1, Tianqiao Huang2, Yifan Yang1, Ling Feng3, Jugao Fang4.   

Abstract

PURPOSE: To investigate the potential mechanisms of miR-211-3p on induction chemotherapy (IC) sensitivity in hypopharyngeal squamous cell carcinoma (HSCC).
METHODS: qRT-PCR was assessed to compare the miR-211-3p expression between IC sensitive and insensitive tumor tissues. The MTT assay was performed to analyze cell proliferation and viability to paclitaxel after alteration of miR-211-3p. Flow cytometry assay was conducted to explore cell apoptosis. Transwell assay was used to explore the effect of miR-211-3p on cell migration. Transcriptome sequencing was then performed to select differentially expressed genes (DEGs) after over-expression of miR-211-3p. GO and KEGG enrichment analyses were conducted to annotate DEGs. PPI analysis was conducted to screen candidate genes. The differential expression and survival status of candidate genes were further validated in TCGA-HNSCC data. The single sample GSEA method was used to investigate the association between downstream genes and immune cell infiltration.
RESULTS: miR-211-3p was up-regulated in IC insensitive larynx-hypopharyngeal tumor tissues. Over-expression of miR-211-3p promoted cell proliferation and migration, and inhibited apoptosis. The IC50 value of miR-211-3p overexpression (OE) group was significantly higher than negative control (NC) group treated with paclitaxel, suggesting miR-211-3p enhanced IC insensitivity in HSCC. We found 778 DEG after over-expression of miR-211-3p and 11 significant genes were then identified. Finally, colony stimulating factor 2 (CSF2) and C-C motif chemokine ligand 20 (CCL20) were validated to be significantly high expressed and associated with poorer overall survival in head and neck squamous cell carcinoma, which were involved in TNF signaling pathway and then regulated immune cell infiltration.
CONCLUSION: The miR-211-3p could promote HSCC progression and upregulate CSF2/CCL20/TNF signaling to promote IC insensitivity in HSCC, which may provide new ideas for HSCC therapy.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Hypopharyngeal squamous cell carcinoma (HSCC); Induction chemotherapy (IC); miR-211-3p

Mesh:

Substances:

Year:  2022        PMID: 35397087     DOI: 10.1007/s11033-022-07401-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  27 in total

1.  clusterProfiler: an R package for comparing biological themes among gene clusters.

Authors:  Guangchuang Yu; Li-Gen Wang; Yanyan Han; Qing-Yu He
Journal:  OMICS       Date:  2012-03-28

2.  Neoadjuvant Chemotherapy for Hypopharyngeal Squamous Cell Carcinoma and Personalized Medicine in Head and Neck Cancer.

Authors:  Eli Gordin
Journal:  Ann Surg Oncol       Date:  2018-01-16       Impact factor: 5.344

3.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

4.  Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.

Authors:  Katrien Van Roosbroeck; Francesca Fanini; Tetsuro Setoyama; Cristina Ivan; Cristian Rodriguez-Aguayo; Enrique Fuentes-Mattei; Lianchun Xiao; Ivan Vannini; Roxana S Redis; Lucilla D'Abundo; Xinna Zhang; Milena S Nicoloso; Simona Rossi; Vianey Gonzalez-Villasana; Rajesha Rupaimoole; Manuela Ferracin; Fortunato Morabito; Antonino Neri; Peter P Ruvolo; Vivian R Ruvolo; Chad V Pecot; Dino Amadori; Lynne Abruzzo; Steliana Calin; Xuemei Wang; M James You; Alessandra Ferrajoli; Robert Orlowski; William Plunkett; Tara M Lichtenberg; Ramana V Davuluri; Ioana Berindan-Neagoe; Massimo Negrini; Ignacio I Wistuba; Hagop M Kantarjian; Anil K Sood; Gabriel Lopez-Berestein; Michael J Keating; Muller Fabbri; George A Calin
Journal:  Clin Cancer Res       Date:  2016-11-30       Impact factor: 12.531

5.  microRNA-10b confers cisplatin resistance by activating AKT/mTOR/P70S6K signaling via targeting PPARγ in esophageal cancer.

Authors:  Kai Wu; Yamei Hu; Kanglu Yan; Yu Qi; Chunyang Zhang; Dengyan Zhu; Donglei Liu; Song Zhao
Journal:  J Cell Physiol       Date:  2019-07-02       Impact factor: 6.384

Review 6.  MicroRNA.

Authors:  Thomas X Lu; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2017-10-23       Impact factor: 10.793

Review 7.  Survival trends in hypopharyngeal cancer: a population-based review.

Authors:  J Robert Newman; Timothy M Connolly; Elisa A Illing; Meredith L Kilgore; Julie L Locher; William R Carroll
Journal:  Laryngoscope       Date:  2014-09-15       Impact factor: 3.325

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity.

Authors:  J Xue; Y Chi; Y Chen; S Huang; X Ye; J Niu; W Wang; L M Pfeffer; Z-M Shao; Z-H Wu; J Wu
Journal:  Oncogene       Date:  2015-04-13       Impact factor: 9.867

10.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.

Authors:  Michael I Love; Wolfgang Huber; Simon Anders
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.